ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Estrogen Can Benefit Women With Metastatic Breast Cancer

January 30, 2009

Brinker Again To Lead Komen As CEO

December 11, 2009

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

October 2, 2009

Advisory Groups: Nominations Sought For Director’s Consumer Liaision Group

June 13, 1997

Grossman Leads Neuro-Oncology Society; NYU Recruits Radiation Oncology Director.

January 14, 2000

In Brief: Congress Corrects An Inequity; Califano Gets a Health Assistant – Fordham Of N.C.

March 25, 1977